The current methods and compositions provide for therapeutic approaches to treating hepatocellular carcinoma (HCC) and other types of cancer including, for example, pancreatic and colon cancer. Accordingly, certain aspects of the disclosure relates to methods and compositions for treating HCC, pancreatic and colon cancer using one or more small molecule inhibitors disclosed herein. In certain embodiments, the small molecule inhibitor is a benzothiazine, a sulfonamide, a thiazolidinone or other chemical compound.

An isothiocyanate functional surfactant, wherein the protonated form of the surfactant includes the structure of formula (IA):

##STR00001##

wherein R.sub.1 includes the structure of formula (IIA), (IIIA), or (IVA),

##STR00002##

wherein X includes an integer ranging from approximately 0 to approximately 20, wherein R.sub.2 comprises a linear or branched aliphatic group containing approximately 8 to approximately 25 carbon atoms, and wherein R.sub.3 comprises an aliphatic or aromatic group containing approximately 1 to approximately 20 carbon atoms and at least one —N═C═S group.

An isothiocyanate functional surfactant, wherein the protonated form of the surfactant includes the structure of formula (IA):

##STR00001##

wherein R.sub.1 includes the structure of formula (IIA), (IIIA), or (IVA),

##STR00002##

wherein X includes an integer ranging from approximately 0 to approximately 20, wherein R.sub.2 comprises a linear or branched aliphatic group containing approximately 8 to approximately 25 carbon atoms, and wherein R.sub.3 comprises an aliphatic or aromatic group containing approximately 1 to approximately 20 carbon atoms and at least one —N═C═S group.

The present invention provides an anti-inflammatory type immune-enhancing agent that simultaneously induces an anti-inflammatory action and an immune-enhancing action. An anti-inflammatory type immune-enhancing agent containing at least one kind selected from a heterocyclic compound represented by the formula (I)

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof, and an isothiocyanate compound represented by the formula S═C═N—R.sup.5 (II) wherein the symbol is as described in the DESCRIPTION, as an active ingredient.

The present invention provides an anti-inflammatory type immune-enhancing agent that simultaneously induces an anti-inflammatory action and an immune-enhancing action. An anti-inflammatory type immune-enhancing agent containing at least one kind selected from a heterocyclic compound represented by the formula (I)

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof, and an isothiocyanate compound represented by the formula S═C═N—R.sup.5 (II) wherein the symbol is as described in the DESCRIPTION, as an active ingredient.

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: ##STR00001##

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: ##STR00001##

Compositions and methods are presented that help reduce cellular ageing, improve cellular stress resilience, and/or promote increased longevity. Especially preferred compositions include a combination of a purine alkaloid, an isothiocyanate or thioglucoside, and a metal-containing antioxidant, where the purine alkaloid, the isothiocyanate or thioglucoside, and the metal-containing antioxidant may be chemically isolated compounds or extracts or other preparations from naturally occurring entities such as plants, bacteria, yeast, etc. Advantageously, contemplated compositions will be effective to reduce and repair oxidative stress, improve mitochondrial function, augment DNA repair and telomere maintenance, increase fatty acid metabolism, and modulate histone deacetylation.

Compositions and methods are presented that help reduce cellular ageing, improve cellular stress resilience, and/or promote increased longevity. Especially preferred compositions include a combination of a purine alkaloid, an isothiocyanate or thioglucoside, and a metal-containing antioxidant, where the purine alkaloid, the isothiocyanate or thioglucoside, and the metal-containing antioxidant may be chemically isolated compounds or extracts or other preparations from naturally occurring entities such as plants, bacteria, yeast, etc. Advantageously, contemplated compositions will be effective to reduce and repair oxidative stress, improve mitochondrial function, augment DNA repair and telomere maintenance, increase fatty acid metabolism, and modulate histone deacetylation.

The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.